The archive doesn't draw a sharp definitional line between the two, but the operational differences are substantial. Both face the same core bottleneck: commercialisation and regulatory complexity dwarf what typical SaaS founders encounter [#333].
The capital gap is the clearest distinction. A Series A in healthtech runs around $10m; biotech asks for roughly double at Series B, and $100m+ is common by Series B in biotech because clinical trials are capital-intensive [#270]. Healthtech accommodates multiple business models and customer types; biotech has fewer acquisition paths and only three to five truly credible buyers globally in most niches [#388]. Funding dynamics have also diverged lately, with biotech remaining relatively better capitalised than healthtech [#368].
That said, the line blurs in practice. The expertise required—hiring scientists, understanding regulatory pathways, managing investor expectations—overlaps significantly enough that founders and teams often move fluidly between both worlds [#389]. It's less a bright border than a spectrum shaped by capital intensity, trial requirements, and acquirer concentration.
Search 450+ episodes and 42,000 chunks of healthtech conversation.